GALWAY, Ireland - Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced on Thursday that its board of directors has approved a quarterly cash dividend of $0.70 per ordinary share for the second quarter of fiscal year 2025. This dividend is in line with the company's previous announcement in May 2024 of an increase in its dividend payments.
The declared dividend will be payable on October 11, 2024, to shareholders who are on record as of September 27, 2024. Medtronic's commitment to shareholder returns is underscored by its inclusion in the S&P 500 Dividend Aristocrats index, a testament to its track record of increasing annual dividend payments for 47 consecutive years.
Medtronic, headquartered in Galway, Ireland, operates on a global scale with a workforce of over 95,000 people in more than 150 countries. The company's mission revolves around alleviating pain, restoring health, and extending life through the development and distribution of advanced medical technologies. Medtronic's diverse portfolio addresses 70 health conditions and includes cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems, among others.
The company's commitment to innovation is reflected in its impact on patient care, claiming to transform the lives of two people every second through its technologies. Medtronic's approach to healthcare solutions emphasizes insight-driven care and prioritizes patient experiences while striving for improved outcomes worldwide.
Medtronic's press release also contains forward-looking statements that are subject to risks and uncertainties, as detailed in the company's periodic reports filed with the Securities and Exchange Commission. As such, actual results could vary significantly from those projected.
This dividend announcement is based on a press release statement from Medtronic plc and serves to provide shareholders and the wider market with the latest information on the company's financial distributions.
In other recent news, Medtronic, a leading medical technology company, has been the subject of various analyst ratings. TD Cowen has maintained its Buy rating and $95.00 stock price target for the company, following the company's confirmation of its financial guidance. The firm's analysis suggests that Medtronic's first fiscal quarter performance should align with or exceed market expectations, with revenues of approximately $7.90 billion and earnings per share (EPS) of $1.20.
On the other hand, Stifel downgraded Medtronic from Buy to Hold and lowered its price target to $85.00, citing slower-than-anticipated growth opportunities and competitive challenges. UBS upgraded the company's stock from Sell to Neutral due to renewed confidence in the Diabetes business segment. Truist Securities also revised its price target for Medtronic, lowering it to $85 from $88, based on the company's mid-single-digit earnings per share (EPS) growth prospects.
In terms of product developments, Medtronic has received FDA approval for its new Simplera™ continuous glucose monitor (CGM) and announced a global partnership with Abbott to expand CGM options for individuals with diabetes. This collaboration is expected to contribute positively to the company's Diabetes revenue.
Despite leadership changes, with CFO Karen Parkhill set to join HP Inc (NYSE:HPQ). and Gary Corona assuming the interim CFO role, Medtronic has reiterated its financial outlook for the first quarter and full fiscal year of 2025. These are the latest developments in the company's ongoing efforts to manage its financial health and advance its product pipeline.
InvestingPro Insights
Medtronic plc (NYSE:MDT) continues to demonstrate its commitment to shareholder returns with the recent declaration of its quarterly cash dividend. The company's financial health and strategic market position are reflected in key metrics and insights from InvestingPro. With a robust market capitalization of $107.29 billion and a consistent record of dividend growth, Medtronic remains a prominent player in the Healthcare Equipment & Supplies industry.
InvestingPro Tips indicate that Medtronic has raised its dividend for 10 consecutive years and has maintained dividend payments for an impressive 48 consecutive years, showcasing a strong commitment to returning value to shareholders. Moreover, the company's stock generally trades with low price volatility, providing a degree of stability in an investor's portfolio.
From a financial perspective, Medtronic's price-to-earnings (P/E) ratio stands at 30.25, with an adjusted P/E ratio for the last twelve months as of Q4 2024 at 22.47, suggesting a favorable valuation compared to historical earnings. The company's revenue growth for the same period was 3.64%, indicating a steady increase in its financial performance. Furthermore, Medtronic's gross profit margin of 65.73% reflects its ability to maintain profitability and operational efficiency. These data points, coupled with a dividend yield of 3.35% as of the last dividend ex-date, make a compelling case for the company's financial stability and attractiveness to dividend-seeking investors.
For those seeking more detailed analysis and additional insights, InvestingPro offers a range of tips, with a total of 9 InvestingPro Tips available on their platform, including predictions on profitability and stock performance. Interested readers can find these tips at: https://www.investing.com/pro/MDT.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.